Linda Sasset

Linda Sasset

Auto-generated profile, based on publicly available information

Linda Sasset

RenBio Inc., Long Island City, New York, NY 11101, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
LSLinda Sasset
Linda Sasset
YZYi Zhang
Yi Zhang
TDTeresa M. Dunn
Teresa M. Dunn
ALAnnarita Di Lorenzo
Annarita Di Lorenzo

20 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
IGIlaria Del Gaudio
Ilaria Del Gaudio
LRLuisa Rubinelli
Luisa Rubinelli
LSLinda Sasset
Linda Sasset
CWChristian Wadsack
Christian Wadsack
THTimothy Hla
Timothy Hla
ALAnnarita Di Lorenzo
Annarita Di Lorenzo
Background: Most of the circulating sphingosine‐1‐phosphate (S1P) is bound to ApoM (apolipoprotein M) of high‐density lipoprotein (HDL) and mediates many beneficial effects of HDL on the vasculature via G protein–coupled S1P receptors. HDL‐bound S1P is decreased in atherosclerosis, myocardial infarction, and diabetes mellitus. In addition to being the target, the endothelium is a source of S1P, which is transported outside of the cells by Spinster‐2, contributing to circulating S1P as well as to local signaling. Mice lacking endothelial S1P receptor 1 are hypertensive, suggesting a vasculoprotective role of S1P signaling. This study investigates the role of endothelial‐derived S1P and ApoM‐bound S1P in regulating vascular tone and blood pressure. Methods and Results: ApoM knockout (ApoM KO) mice and mice lacking endothelial Spinster‐2 (ECKO‐Spns2) were infused with angiotensin II for 28 days. Blood pressure, measured by telemetry and tail‐cuff, was significantly increased in both ECKO‐Spns2 and ApoM KO versus control mice, at baseline and following angiotensin II. Notably, ECKO‐Spns2 presented an impaired vasodilation to flow and blood pressure dipping, which is clinically associated with increased risk for cardiovascular events. In hypertension, both groups presented reduced flow‐mediated vasodilation and some degree of impairment in endothelial NO production, which was more evident in ECKO‐Spns2. Increased hypertension in ECKO‐Spns2 and ApoM KO mice correlated with worsened cardiac hypertrophy versus controls. Conclusions: Our study identifies an important role for Spinster‐2 and ApoM‐HDL in blood pressure homeostasis via S1P‐NO signaling and dissects the pathophysiological impact of endothelial‐derived S1P and ApoM of HDL‐bound S1P in hypertension and cardiac hypertrophy.

11 July 2022 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
LSLinda Sasset
Linda Sasset
OMOnorina Laura Manzo
Onorina Laura Manzo
YZYi Zhang
Yi Zhang
AMAlice Marino
Alice Marino
LRLuisa Rubinelli
Luisa Rubinelli
ALAnnarita Di Lorenzo
Annarita Di Lorenzo
Growing evidence correlate the accrual of the sphingolipid ceramide in plasma and cardiac tissue with heart failure (HF). Regulation of sphingolipid metabolism in the heart and the pathological impact of its derangement remain poorly understood. Recently, we discovered that Nogo-B, a membrane protein of endoplasmic reticulum, abundant in the vascular wall, down-regulates the sphingolipid de novo biosynthesis via serine palmitoyltransferase (SPT), first and rate liming enzyme, to impact vascular functions and blood pressure. Nogo-A, a splice isoform of Nogo, is transiently expressed in cardiomyocyte (CM) following pressure overload. Cardiac Nogo is up-regulated in dilated and ischaemic cardiomyopathies in animals and humans. However, its biological function in the heart remains unknown. We discovered that Nogo-A is a negative regulator of SPT activity and refrains ceramide de novo biosynthesis in CM exposed to haemodynamic stress, hence limiting ceramide accrual. At 7 days following transverse aortic constriction (TAC), SPT activity was significantly up-regulated in CM lacking Nogo-A and correlated with ceramide accrual, particularly very long-chain ceramides, which are the most abundant in CM, resulting in the suppression of ‘beneficial’ autophagy. At 3 months post-TAC, mice lacking Nogo-A in CM showed worse pathological cardiac hypertrophy and dysfunction, with ca. 50% mortality rate. Mechanistically, Nogo-A refrains ceramides from accrual, therefore preserves the ‘beneficial’ autophagy, mitochondrial function, and metabolic gene expression, limiting the progression to HF under sustained stress.

1 November 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LSLinda Sasset
Linda Sasset
GPGianluca Petris
Gianluca Petris
FCFrancesca Cesaratto
Francesca Cesaratto
Oscar Roberto BurroneOscar Roberto Burrone
Oscar Roberto Burrone
Endoplasmic reticulum-associated degradation (ERAD) is an essential quality control mechanism of the folding state of proteins in the secretory pathway that targets unfolded/misfolded polypeptides for proteasomal degradation. The cytosolic p97/valosin-containing protein is an essential ATPase for degradation of ERAD substrates. It has been considered necessary during retro-translocation to extract proteins from the endoplasmic reticulum that are otherwise supposed to accumulate in the endoplasmic reticulum lumen. The activity of the p97-associated deubiquitinylase YOD1 is also required for substrate disposal. We used the in vivo biotinylation retro-translocation assay in mammalian cells under conditions of impaired p97 or YOD1 activity to directly discriminate their requirements and diverse functions in ERAD. Using different ERAD substrates, we found that both proteins participate in two distinct retro-translocation steps. For CD4 and MHC-Iα, which are induced to degradation by the HIV-1 protein Vpu and by the CMV immunoevasins US2 and US11, respectively, p97 and YOD1 have a retro-translocation-triggering role. In contrast, for three other spontaneous ERAD model substrates (NS1, NHK-α1AT, and BST-2/Tetherin), p97 and YOD1 are required in the downstream events of substrate deglycosylation and proteasomal degradation.

1 January 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GPGianluca Petris
Gianluca Petris
ACAntonio Casini
Antonio Casini
LSLinda Sasset
Linda Sasset
FCFrancesca Cesaratto
Francesca Cesaratto
MBMarco Bestagno
Marco Bestagno
Oscar Roberto BurroneOscar Roberto Burrone
Oscar Roberto Burrone
CD4 and BST-2/Tetherin are cellular membrane proteins targeted to degradation by the HIV-1 protein Vpu. In both cases proteasomal degradation following recruitment into the ERAD pathway has been described. CD4 is a type I transmembrane glycoprotein, with four extracellular immunoglobulin-like domains containing three intrachain disulfide bridges. BST-2/Tetherin is an atypical type II transmembrane glycoprotein with an N-terminal transmembrane domain and a C-terminal glycophosphatidylinositol anchor, which dimerizes through three interchain bridges. We investigated spontaneous and Vpu-induced retro-translocation of CD4 and BST-2/Tetherin using our novel biotinylation technique in living cells to determine ER-to-cytosol retro-translocation of proteins. We found that CD4 retro-translocates with oxidized intrachain disulfide bridges, and only upon proteasomal inhibition does it accumulate in the cytosol as already reduced and deglycosylated molecules. Similarly, BST-2/Tetherin is first exposed to the cytosol as a dimeric oxidized complex and then becomes deglycosylated and reduced to monomers. These results raise questions on the required features of the putative retro-translocon, suggesting alternative retro-translocation mechanisms for membrane proteins in which complete cysteine reduction and unfolding are not always strictly required before ER to cytosol dislocation.

1 January 2019 in Journal of Molecular Biology
Verified
Journal Article
Closed access
FCFrancesca Cesaratto
Francesca Cesaratto
LSLinda Sasset
Linda Sasset
MMMichael P. Myers
Michael P. Myers
ARAngela Re
Angela Re
GPGianluca Petris
Gianluca Petris
Oscar Roberto BurroneOscar Roberto Burrone
Oscar Roberto Burrone